FILING ANALYSIS · MONDAY, NOVEMBER 2
BIOMARIN PHARMACEUTICAL INC BMRN — 8-K: Results of Operations and Financial Condition
positive
BioMarin's Q3 revenue grew 32% year-over-year to $1.025 billion, driven by a 44% increase in Metabolic Conditions and a 12% increase in Skeletal Conditions, but the company updated its full-year guidance to reflect order timing uncertainty and the impact of two acquired in-process research and development charges.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →